Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 10th, 2026

LECO_Weekly-Healthcare-News_8-10-2026Download

Healthcare Weekly News and Deals

  1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
  2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
  3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
  4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
  5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
  6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
  7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
  8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
  9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
  10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
  11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
  12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
  13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
  14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
  15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
  16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
  17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
  18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
  19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
  20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
  21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
  22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
  23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
  24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
  25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
  26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
  27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
  28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
  29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
  30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
  31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

  1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
  2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
  3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
  4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
  5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 8th, 2026

LECO_Weekly-Healthcare-News_6-8-2026Download

Healthcare Weekly News and Deals –June 8th, 2026

  1. New Brunswick, NJ-based Johnson & Johnson (NYSE: JNJ) agreed to acquire Firefly Bio, Inc. for $1 billion in cash to add its Firelink™ degrader antibody conjugate (DAC) platform targeting KRAS-driven and other hard-to-treat solid tumors, expanding J&J’s next-generation oncology pipeline Johnson & Johnson (NYSE: JNJ) announced on June 8, 2026 a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company developing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ platform delivers a highly selective protein degrader to tumor cells while avoiding healthy cells, targeting KRAS-driven solid tumors — among the most prevalent and historically hard-to-treat oncology targets. The acquisition adds preclinical candidates and a novel modality complementing J&J’s existing antibody engineering expertise across monoclonal antibodies, bispecifics, and ADCs. Closing is expected later in 2026, subject to regulatory approvals and customary conditions. (Link)
  2. Wilmington, Delaware-based Incyte Corporation (NASD: INCY) agreed to acquire Vega Therapeutics — a wholly owned subsidiary of Star Therapeutics — for $1.25 billion upfront plus up to $750 million in sales milestones (up to $2.0 billion total), adding VGA039, a Phase 3-ready first-in-class monoclonal antibody for von Willebrand disease Incyte Corporation (NASD: INCY) announced on June 8, 2026 a definitive agreement to acquire Vega Therapeutics, Inc. from Star Therapeutics, LLC for $1.25 billion upfront plus up to $750 million in sales milestone payments, totaling up to $2.0 billion. Vega’s lead candidate, VGA039, is a first-in-class investigational monoclonal antibody modulating Protein S to improve hemostasis in von Willebrand disease (VWD) — the most common inherited bleeding disorder, affecting approximately 135,000 diagnosed U.S. patients. VGA039 is in Phase 3 pivotal development as a potentially first-ever subcutaneous prophylactic therapy for VWD patients who currently require frequent IV infusions; it holds FDA Breakthrough Therapy and Orphan Drug designations. Closing is expected in Q3 2026, subject to antitrust clearance. (Link)
  3. Nashville-based Ascension health system finalized its $3.9 billion acquisition of ASC operator AMSURG — adding 250 ambulatory surgery centers across 34 states — after the FTC required divestitures of seven surgery centers, creating one of the largest nonprofit health system-owned ambulatory surgery portfolios in the country Ascension, one of the largest nonprofit health systems in the United States, closed its $3.9 billion acquisition of AMSURG following an FTC consent order requiring divestiture of seven ASCs in five metropolitan markets to SCA Health — a subsidiary of UnitedHealth Group’s (NYSE: UNH) Optum — and one additional ASC. The acquisition adds 250 ASCs across 34 states to Ascension’s existing portfolio of 58 wholly owned surgical centers, dramatically expanding its outpatient surgery footprint. Industry observers view the deal as a catalyst for broader ASC sector consolidation. (Link)
  4. Joplin, Missouri-based Freeman Health System completed the $110 million acquisition of Northwest Health from Community Health Systems (NYSE: CYH), adding four Arkansas hospital facilities and marking Freeman’s first expansion into the state Freeman Health System finalized the $110 million purchase of Northwest Health from Community Health Systems (NYSE: CYH). The transaction included substantially all assets of four hospitals — Northwest Medical Center Bentonville, Northwest Medical Center Springdale, Willow Creek Women’s Hospital in Johnson, and Siloam Springs Regional Hospital — plus associated outpatient centers and practices, bringing approximately 2,200 employees into the Freeman organization. The deal marks Freeman Health’s inaugural geographic expansion into Arkansas, adding significant hospital density in the rapidly growing Northwest Arkansas market. (Link)
  5. Aveanna Healthcare Holdings (NASD: AVAH) has completed the acquisition of Family First Homecare for $175.5 million, adding 27 pediatric home care locations across seven states to its national platform. Atlanta-based Aveanna Healthcare Holdings (NASD: AVAH), a diversified home care platform serving medically complex patient populations, has closed its $175.5 million all-cash acquisition of Family First Homecare, a scaled multi-state provider of pediatric private duty nursing services. Funded entirely from cash on hand, the transaction adds 27 locations across Florida, Illinois, Iowa, North Carolina, Pennsylvania, South Dakota, and Texas to Aveanna’s portfolio. The deal lifts Aveanna’s full-year 2026 revenue guidance by $70 million to a range of $2.63–$2.65 billion, and increases its Adjusted EBITDA guidance by $10 million to a range of $338–$342 million, reflecting immediate financial accretion from the deal. (Link)
  6. Parsippany, NJ-based Med-Metrix (PE: Harvest Partners and A&M Capital Partners) entered into a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash, strengthening its mid-revenue cycle technology platform PE-backed Med-Metrix, supported by Harvest Partners (~$20 billion AUM) and A&M Capital Partners, signed a definitive agreement to acquire Vitalware from Health Catalyst (NASD: HCAT) for $147 million in cash. Vitalware is a Best-in-KLAS mid-revenue cycle software business generating approximately $37 million in FY2025 revenue; its cloud-based chargemaster management, revenue integrity, and coding optimization tools strategically expand Med-Metrix’s platform. For Health Catalyst, the divestiture proceeds retire its ~$160 million senior secured term loan, sharpening the company’s strategic focus. Vitalware was founded in 2011 and acquired by Health Catalyst in 2020. (Link)
  7. New Haven, CT-based Rallybio Corporation (NASD: RLYB) and San Diego-based Avenzo Therapeutics announced a definitive merger agreement — combined company to operate as Avenzo Therapeutics advancing next-generation oncology small molecules and ADCs Rallybio Corporation (NASD: RLYB) and Avenzo Therapeutics announced on June 1, 2026 a definitive merger under which Rallybio acquires Avenzo, with the combined company operating as Avenzo Therapeutics. A concurrent oversubscribed $215 million private placement from healthcare institutional investors and mutual funds funds operations into late 2028 and supports advancement through multiple clinical milestones across next-generation oncology small molecules and ADCs. Pre-transaction Rallybio stockholders will own approximately 2.8% of the combined company; Rallybio intends to distribute substantially all pre-closing net cash to existing stockholders. Closing expected Q4 2026, subject to stockholder approval. (Link)
  8. Murfreesboro, Tennessee-based National HealthCare Corporation (NYSE American: NHC) completed the $50.5 million acquisition of five skilled nursing facilities, converting decades-long management agreements into full ownership across 566 operating beds National HealthCare Corporation (NYSE American: NHC) announced on June 4, 2026 the closing of the $50.5 million purchase of five skilled nursing facilities — four in Tennessee and one in South Carolina, totaling 566 operating beds — from National Health Corporation (an ESOP entity). NHC subsidiaries have managed these facilities since 1988; the acquisition gives NHC full ownership of both operations and real estate. CEO Steve Flatt noted the transition is invisible to patients and partners and will be immediately accretive to cash flow and earnings. (Link)
  9. Westlake Village, California-based LTC Properties (NYSE: LTC) announced a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona — welcoming MorningStar Senior Living as its eleventh SHOP operator and ninth new partner since the platform’s May 2025 launch LTC Properties, Inc. (NYSE: LTC) announced on June 2, 2026 a $54 million SHOP acquisition of a 104-unit assisted living and memory care community in Phoenix, Arizona, at a 6.75% cap rate with an expected unlevered IRR in the low-to-mid teens. The community will continue to be managed by MorningStar Senior Living — new to LTC and its eleventh SHOP operating partner. Since its SHOP launch, LTC has completed $524 million in SHOP acquisitions, including $171 million in 2026, with SHOP now representing approximately 28% of annualized NOI and 32% of gross investments. LTC targets an additional $285 million in SHOP acquisitions closing by end of Q3 2026. (Link)
  10. New York-based Strata Critical Medical (NASD: SRTA) completed the all-cash acquisition of Louisville Perfusion Services, Inc., a regional perfusion and blood management provider serving cardiac surgery programs in Kentucky, for up to $20 million — adding a Midwest and Southern stronghold to its 275+ hospital national perfusion platform Strata Critical Medical (NASD: SRTA) announced on June 2, 2026 the completed acquisition of Louisville Perfusion Services, Inc. (LPS), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky. The transaction consists of approximately $16 million upfront plus up to $4 million in performance-based consideration. LPS is expected to generate approximately $10 million in revenue and $3 million in Adjusted EBITDA for 2026. The deal expands Strata’s cardiac perfusion platform into the Midwest and Southern U.S., adds ECMO support and organ transplant capabilities, and is consistent with Strata’s strategy of bolt-on acquisitions at mid-single digit Adjusted EBITDA multiples. (Link)
  11. Frisco, Texas-based Soleo Health (PE: Court Square Capital Partners and WindRose Health Investors) acquired Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs, adding a specialty pharmacy and ambulatory infusion center in North Carolina and bringing its national portfolio to 28 specialty pharmacies and 30+ infusion suites Soleo Health, a portfolio company of Court Square Capital Partners and WindRose Health Investors, acquired both Realo Specialty Care Pharmacy and BluHaven Management from Realo Drugs. The dual acquisition adds a specialty pharmacy in Morrisville, N.C., and an ambulatory infusion center in Raleigh, N.C., deepening Soleo’s presence in North Carolina, South Carolina, Virginia, and Maryland. The deal brings Soleo’s national portfolio to 28 specialty pharmacies and over 30 ambulatory infusion suites. (Link)
  12. Salt Lake City-based Bristol Hospice acquired Hope Hospice and Palliative Care, expanding its presence into the greater Memphis, Tennessee market Bristol Hospice, one of the largest hospice providers in the United States, announced on June 1, 2026 the acquisition of Hope Hospice and Palliative Care, bringing compassionate end-of-life services into the greater Memphis community. The acquisition honors Hope Hospice’s legacy of patient-centered care while integrating it into Bristol’s national network and clinical infrastructure. Bristol operates dozens of locations nationwide. (Link)
  13. Southlake, Texas-based Alliance Clinical Network (PE: Amulet Capital Partners and BPOC) completed a strategic merger with Atlas Clinical Research, creating an expanded national clinical trial site network across seven states with nearly 50 years of combined clinical research experience Alliance Clinical Network and Atlas Clinical Research announced on June 2, 2026 the closing of their strategic merger, combining nearly 50 years of collective clinical research experience across sites in Arizona, California, Florida, Nevada, New York, Pennsylvania, and Texas. The combined organization serves sponsors across CNS disorders, internal medicine, women’s health, metabolic diseases, dermatology, gastroenterology, pain management, and vaccines. Alliance is backed by Amulet Capital Partners and BPOC; Anthony Milonas serves as CEO. The merger was originally announced May 13, 2026. (Link)
  14. Marietta, Georgia-based Wellstar Health System finalized an agreement to acquire Mountain Lakes Medical Center, a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Georgia, expanding its hospital portfolio from 11 to 12 facilities Wellstar Health System announced a definitive agreement to acquire Mountain Lakes Medical Center (MLMC), a 25-bed critical access hospital and Level IV Trauma Center in Clayton, Ga., serving Rabun County and surrounding northeast Georgia and western North Carolina. The acquisition is expected to close August 1 pending regulatory approvals. Wellstar’s strategic rationale centers on connecting MLMC patients to expanded specialty resources, digital health capabilities, and advanced clinical programs across its growing Georgia footprint. (Link)
  15. New York-based National Healthcare Properties (NASD: NHP), a senior housing REIT, announced approximately $279 million in signed purchase agreements and letters of intent for SHOP acquisitions expected to add 1,214 units to its existing 3,615-unit portfolio National Healthcare Properties (NASD: NHP) announced on June 1, 2026 signed purchase and sale agreements or non-binding letters of intent for approximately $279 million of SHOP acquisitions, with estimated weighted average year-one and year-three cap rates of 8.0% and 9.7%, respectively. The pipeline is expected to add 1,214 units to NHP’s existing 3,615 needs-based senior housing units. NHP also announced its Class A common stock will be added to the Russell 2000 and 3000 Indexes effective after market close on June 26, 2026, following its April 2026 NASD listing. (Link)
  16. Irvine, California-based Discovery Behavioral Health announced an agreement with lender HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt obligations, following a December 2025 lender seizure of the company; regulatory approval pending Discovery Behavioral Health — one of the largest behavioral health platforms in the country, formerly backed by Webster Equity Partners — announced on June 2, 2026 an agreement with HPS Investment Partners to transfer majority ownership in exchange for a substantial reduction of its $280 million debt burden. HPS and Capital One originally seized Discovery’s assets in December 2025 after repeated covenant defaults on debt agreements originally entered in June 2021. Discovery briefly contested the takeover in New York state court before abandoning the effort. The announcement formalizes the ownership transfer structure pending regulatory approvals; a CEO change was also announced simultaneously. (Link)
  17. Radnor, Pennsylvania-based Hidden River Strategic Capital invested debt and convertible preferred equity into Redding, California-based Northstar Senior Living to support its merger with North Palm Beach, Florida-based Alta Senior Living, creating a scaled national senior living management platform Hidden River Strategic Capital announced on June 2, 2026 an investment in Northstar Senior Living in connection with its merger with Alta Senior Living. The combined company will operate as Northstar Senior Living, managing assisted living, memory care, and independent living communities under long-term contracts with community owners across the U.S. Hidden River’s investment consisted of debt and convertible preferred equity. Northstar’s executive team will run day-to-day operations; Alta CEO Doug Brawn will serve as Board Chair. Blueprint CRE facilitated the capital partner search and merger. (Link)
  18. San Francisco-based Clarify Health completed the acquisition of Loyal Health Holdings to create healthcare’s first closed-loop network intelligence and patient activation platform, combining referral analytics with AI-powered patient engagement tools across nearly 500 hospitals Clarify Health completed the acquisition of Loyal Health Holdings, Inc., a healthcare-specific patient activation platform, creating what the combined company describes as the industry’s first closed-loop network intelligence engine spanning referral intelligence, patient activation, and outcomes measurement. Loyal’s Care Activation Platform manages over 80,000 provider and location profiles and serves nearly 500 hospitals nationwide. The merged entity pairs Clarify’s Meridian® machine learning platform with Loyal’s AI-powered scheduling, chat, and predictive propensity engines. Clarify CEO Todd Gottula leads the combined company. (Link)
  19. San Juan Capistrano-based The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa The Ensign Group (NASD: ENSG) acquired the real estate and operations of Woodland Health and Rehabilitation, a 62-bed skilled nursing facility in Mount Pleasant, Iowa, effective June 1, 2026, through a Standard Bearer Healthcare REIT, Inc. subsidiary. The facility will be operated by an Ensign-affiliated tenant. The acquisition brings Ensign’s total portfolio to 396 healthcare operations across 17 states. (Link)
  20. The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026, through its Standard Bearer Healthcare REIT subsidiary — to be leased to a third-party operator under a long-term triple net lease Through a subsidiary of Standard Bearer Healthcare REIT, The Ensign Group (NASD: ENSG) acquired the real estate of Memory Care of Contra Costa, a 46-unit memory care facility in Pleasant Hill, California, effective June 1, 2026. The facility will be operated by an experienced third-party operator under a long-term triple net lease. CEO Barry Port called the acquisition a ‘home run’ for the Standard Bearer portfolio. Ensign’s real estate subsidiaries now own 181 real estate assets across its national portfolio. (Link)
  21. Poway, California-based Diazyme Laboratories, Inc. (a General Atomics subsidiary) acquired Carolina Liquid Chemistries Corporation, a Greensboro, North Carolina-based FDA-registered manufacturer and value-added reseller of chemistry systems and reagents Diazyme Laboratories, Inc. announced on June 1, 2026 the acquisition of Carolina Liquid Chemistries Corporation (CLC), an FDA-registered manufacturer and value-added reseller of chemistry systems and reagents founded in 1994 in Greensboro, North Carolina. CLC’s cost-effective reagent products will complement Diazyme’s proprietary enzyme and immunoassay technologies, creating synergies for clinical and reference laboratories of all sizes. CLC’s business will be fully integrated into Diazyme’s operations. Diazyme is a cGMP and ISO 13485 certified medical device manufacturer. (Link)
  22. Bridgepoint has acquired Obagi Medical from Waldencast (NASD: WALD) in a transaction valued at up to $460 million, securing a dermatology and aesthetics skincare business European PE firm Bridgepoint has agreed to acquire Obagi Medical from publicly traded beauty holding company Waldencast (NASD: WALD) in a deal worth up to $460 million. Waldencast originally acquired Obagi Medical in 2022 before expanding it into injectable aesthetics through a bolt-on acquisition. The divestiture allows Waldencast to deleverage its balance sheet and redirect investment exclusively toward Milk Makeup. Bridgepoint’s acquisition provides Obagi Medical with focused, dedicated ownership to advance its position in the rapidly growing physician-dispensed dermatology and aesthetics market, which had expanded to include the FDA-approved Obagi Saypha® MagIQ™ dermal filler range prior to the transaction. (Link)
  23. Geneva, Switzerland-based SGS (SIX: SGSN), the world’s leading testing, inspection and certification company, acquired CMIC, INC., a Chicago, Illinois-based specialized bioanalytical testing services provider — its second U.S. bioanalytical acquisition in two months SGS announced on June 3, 2026 the acquisition of CMIC, INC., a Chicago, Illinois-based provider of bioanalytical testing services established in 2010. CMIC’s 27,000-square-foot GLP-compliant facility delivers bioanalysis across pre-clinical and clinical phases for pharmaceutical and biotech manufacturers developing biologics and complex therapies. CMIC, INC. is a group company of CMIC HOLDINGS Co., Ltd., which will continue collaborating with SGS through its pharmaceutical arm. The deal advances SGS’s Strategy 27 objective to double North American sales between 2023 and 2027. SGS operates over 2,500 laboratories across 115 countries.  (Link)
  24. Guildford, UK-based Venture Life Group (AIM: VLG) agreed to acquire two U.S. women’s health consumer brands — FemiClear and CUROXEN — from Austin, Texas-based OrganiCare Nature’s Sciences for up to $28 million, expanding its intimate health portfolio into Walmart, Walgreens, CVS, and Target Venture Life Group plc (AIM: VLG) announced on June 4, 2026 an agreement to acquire the FemiClear and CUROXEN consumer healthcare brands from OrganiCare Nature’s Sciences for up to $28 million — $23 million upfront and up to $5 million in deferred consideration tied to 2026 trading performance, funded from existing cash. FemiClear addresses gynaecological conditions including bacterial vaginosis, genital herpes, thrush, and UTIs (~98% of combined revenues); CUROXEN provides infection prevention for wounds and mouth sores. Combined net revenues were $12.1 million in the 12 months to March 31, 2026, up 29.1% year-on-year. Distribution spans Walmart, Walgreens, CVS, and Target. Venture Life shares rose approximately 9–10% on announcement. (Link)
  25. Suresnes, France-based Servier agreed to acquire the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (NASD: EWTX) for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in milestones — to advance sevasemten, a first-in-class oral fast skeletal myosin inhibitor for Duchenne and Becker muscular dystrophy French pharmaceutical firm Servier announced on June 1, 2026 a definitive agreement to acquire Edgewise Therapeutics’ (NASD: EWTX) muscular dystrophy business for up to $2.65 billion — $1.55 billion upfront plus up to $1.1 billion in regulatory and commercial milestones. The deal secures sevasemten, a first-in-class oral fast skeletal myosin inhibitor in pivotal testing for Becker muscular dystrophy and mid-stage studies for Duchenne. Edgewise retains its cardiovascular pipeline (EDG-7500 for HCM, EDG-15400 for HFpEF) and becomes a cardiovascular-focused company post-close. All Edgewise employees supporting the muscular dystrophy business will receive comparable offers from Servier. Closing is expected in Q3 2026. (Link)

Venture Deals and Other

  1. Charlottesville, Virginia-based Contraline, Inc. closed a $92.5 million Series B co-led by BVF Partners and RA Capital Management — with GV (Google Ventures), Lumira Ventures, and Invus participating — to advance NES/T Gel, a first-in-class daily hormonal male contraceptive, into late-stage development Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced on June 2, 2026 the closing of a $92.5 million Series B co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Proceeds support late-stage development of NES/T Gel — an investigational, daily, topical, hormonal, reversible male contraceptive with first-in-class potential — and advancement of ADAM, a non-hormonal hydrogel implant in clinical trials. BVF’s Iris van Alderwerelt van Rosenburgh joined the Board. No male contraceptive pill or equivalent has been approved in the U.S.; NES/T Gel addresses a massive unmet need in men’s reproductive health. (Link)
  2. Founders Fund has led a $435 million Series C in NewLimit alongside Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others to fund the first human clinical trial of an aging reprogramming medicine. Founders Fund led NewLimit’s $435 million Series C, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning backers including Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. Founded in 2021 by Coinbase (NASD: COIN) CEO Brian Armstrong alongside Blake Byers and CEO Jacob Kimmel, NewLimit is developing epigenetic reprogramming medicines to reverse cellular aging. The raise will fund the company’s lead liver reprogramming therapy into human clinical trials — a timeline dramatically accelerated by a recent prototype breakthrough that demonstrated age reversal in old human liver cells. The company’s long-term vision is to treat aging itself as a clinically addressable condition. (Link)
  3. Felicis, Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation have co-invested in a $50 million Series A for Adaptive Innovations, an AI-native home health provider based in New York and Dallas. Felicis led a $50 million Series A in Adaptive Innovations, the first AI-native homecare provider, with significant participation from Bain Capital Ventures, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, Dorm Room Fund, and Constellation, along with prominent angels from healthcare and frontier AI. The round brings Adaptive’s total funding to $60 million, including a previously undisclosed $10 million Seed. Since its 2025 launch, Adaptive has achieved an industry-leading sub-5% rehospitalization rate versus an 11% industry average, reduced clinician documentation time by 80%, and delivered over 100,000 visits across partnerships with more than 500 healthcare organizations including every major Texas hospital system. Proceeds will fund platform scaling and clinical workforce expansion into new states. (Link)
  4. General Catalyst and Chemistry led a $35 million Series A in Yuzu Health — with Anthropic’s Anthology Fund, Bain Future Back Ventures, Lachy Groom, and Neo — to modernize health insurance TPA infrastructure with AI-automated claims processing Yuzu Health secured $35 million in Series A funding led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund, Bain Future Back Ventures, Timeless Ventures, Lachy Groom, and Neo. Founded in 2022, Yuzu Health is a vertically integrated third-party administrator (TPA) powering claims processing, payments, and member administration for health plans, with a unified data architecture offered as a white-labeled solution. The company automates historically manual workflows including claims adjudication, stop-loss submissions, reconciliation, and downstream reporting, enabling more customizable plan designs including direct contracts and dynamic copays. (Link)
  5. San Francisco-based Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z) — with Night Capital and fintech founders from Superhuman, Plaid, and Wise — to build AI autonomous systems for small healthcare businesses Lassie raised $35 million in Series A led by Andreessen Horowitz (a16z), with Night Capital and prominent fintech founders from Superhuman, Plaid, and Wise participating. a16z’s Alex Rampell joined the board. Lassie’s platform currently operates in more than 700 dental and doctor practices across 49 states, automating front-office, scheduling, billing, and operational workflows so small healthcare practices can run themselves with reduced administrative overhead. (Link)
  6. New York-based Novellia raised $18 million in Series A led by Spark Capital — with Khosla Ventures, Acrew Capital, Bling Capital, and TMV — to scale its patient-controlled real-world data platform providing anonymized health records for drug R&D Novellia, the only real-world data company built entirely on patient-contributed information, announced an $18 million Series A led by Spark Capital with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV, bringing total funding to $28 million. Alongside the raise, Novellia launched its patient-facing mobile app allowing individuals to securely access and contribute their complete health history. Novellia provides structured real-world datasets to top-10 pharma companies for drug development — addressing what the company calls a $50 billion gap in research-grade patient data. Announced June 2, 2026. (Link)
  7. San Diego-based Rejuvenate Bio (a George Church / Harvard Wyss Institute spinout) announced $6 million in financing and a strategic R&D collaboration with Merck Animal Health to advance gene therapies targeting age-related chronic diseases in animals and humans Rejuvenate Bio, a gene therapy company co-founded by Harvard professor George Church as a spinout from the Harvard Wyss Institute, announced on June 8, 2026 a $6 million financing round and a strategic R&D collaboration with Merck Animal Health. Rejuvenate Bio develops gene therapies targeting the root causes of age-related diseases — including heart failure, kidney failure, Type 2 diabetes, and obesity — in both humans and dogs, using its dual-species strategy to build clinical evidence through companion animal studies while advancing toward human therapeutics. Rejuvenate Bio has previously raised over $10 million in its Series A. (Link)
  8. Houston, Texas-based Goldenrod Therapeutics, Inc. completed the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and Fannin Partners to advance 11h — a brain-penetrant PDE4 inhibitor — into Phase I clinical trials for Friedreich’s Ataxia and other neurodegenerative diseases Goldenrod Therapeutics, Inc., a Fannin Innovation-founded precision therapeutics company, announced the initial closing of a $6.5 million Series Seed round led by Ataxia Ventures and an affiliate of Fannin Partners. Proceeds fund manufacturing, formulation optimization, IND-enabling studies, and a Phase I trial in Friedreich’s Ataxia (FA) — a rare and progressive neurodegenerative disease — with pharmacodynamic biomarkers of PDE4 pathway modulation. Goldenrod’s lead candidate, 11h, is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor designed at the University of Nebraska Medical Center (UNMC) to overcome emesis limitations of earlier inhibitors. Development has been supported by NIH and Department of Defense grants. (Link)
  9. Aurora Forge, Jackson Healthcare, Peg’s Foundation, and family offices co-invested a $3 million Seed round in Columbus, Ohio-based Radley Health — alongside existing investor CareSource — to fund expansion of its peer-driven mental health platform into Georgia Aurora Forge, Jackson Healthcare, Peg’s Foundation, and prominent family offices participated in a $3 million Seed round for Radley Health, joining existing investor CareSource, a nonprofit health plan headquartered in Dayton, Ohio. Radley Health has built one of the largest peer support networks in Ohio, with over 450 certified peer support specialists in more than 70 counties across a state where 75 of 88 counties face Mental Health Professional Shortage Area designations. Proceeds support peer workforce growth, healthcare provider partnerships, technology enhancements, and a Georgia market launch where the company has already recruited 50 peer support specialists through partnership with the Georgia Mental Health Consumer Network. (Link)
  10. Enable Ventures, Florida Opportunity Fund, Castellan Group, DeepWork Capital, Sawmill Angels, and Black Opal have jointly invested $5.75 million in Kalogon, a Melbourne, Florida-based smart seating solutions company. Enable Ventures — the first venture fund dedicated to closing the disability wealth gap — led a $5.75 million funding round in Melbourne, Fla.-based Kalogon, a smart seating technology company specializing in seated health solutions for wheelchair users, commercial aviation, and other extended-sitting use cases. Participating investors include Florida Opportunity Fund, Castellan Group, and returning backers DeepWork Capital, Sawmill Angels, and Black Opal. The investment follows a strong year for Kalogon, during which the company more than tripled its medical revenue year-over-year and moved into a dedicated manufacturing facility. Kalogon’s technology is currently being tested to reduce fatigue for U.S. Air Force B-52 and E-4B aircrew on extended missions. Proceeds will fund engineering, R&D, and international expansion. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 11th, 2026

LECO_Weekly-Healthcare-News_5-11-2026Download
  1. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Angelini Pharma S.p.A., an international pharmaceutical company and part of Italy’s Angelini Industries Group, entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a Coral Gables, FL-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, in an all-cash transaction valued at approximately $4.1 billion or $31.50 per share. The deal, announced May 7, 2026, represents a premium to Catalyst’s recent trading prices and will expand Angelini Pharma’s U.S. market presence and rare-disease portfolio, particularly in brain health and neurological conditions. Closing is expected in the third quarter of 2026, subject to Catalyst stockholder approval, regulatory clearances, and other customary conditions. (Link)
  2. Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), the Swiss pharmaceutical and diagnostics giant, entered into a definitive merger agreement to acquire PathAI, a Boston-based AI-powered digital pathology company, for USD 750 million upfront plus up to USD 300 million in milestone payments, valuing the deal at up to USD 1.05 billion. Roche (SIX: RO, ROP; OTCQX: RHHBY) has signed a definitive merger agreement to acquire Boston-based digital pathology firm PathAI. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million, bringing total potential consideration to USD 1.05 billion. Roche has partnered with the company since 2021, expanding their agreement in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche Diagnostics will absorb PathAI as an operating unit after closing expected in H2 2026, pending regulatory clearance, accelerating Roche’s AI-powered diagnostics capabilities. (Link)
  3. Cross Country Healthcare, Inc. (NASD: CCRN), a Boca Raton-based technology-driven healthcare workforce solutions company, entered into a definitive agreement to be acquired by growth-oriented private equity firm Knox Lane in an all-cash transaction valued at approximately $437 million, or $13.25 per share. Cross Country Healthcare (NASDAQ: CCRN) has signed a definitive agreement to be taken private by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million, or $13.25 per share. The price represents a premium of approximately 31% to CCRN’s closing price on May 6, 2026, and a 45% premium to its 90-day volume-weighted average trading price. Knox Lane is a private equity firm with $3.5 billion in assets under management. Upon completion, Cross Country Healthcare will become a privately held platform company in Knox Lane’s portfolio and will cease trading on Nasdaq, with closing expected in Q3 2026.  (Link)
  4. Sanford Health, a Sioux Falls, South Dakota-based nonprofit rural health system, and North Memorial Health, a Twin Cities-based Minnesota nonprofit health system, signed a definitive agreement to combine into a single nonprofit organization, supported by a planned $600 million investment. Sanford Health and North Memorial Health have signed a definitive agreement to combine into a single nonprofit health system. The transaction includes a $600 million investment in Twin Cities services. Sanford’s most recent annual revenue was nearly $11.7 billion in 2025, which reflects its merger with Marshfield Clinic Health System in Wisconsin. Sanford Health President and CEO Bill Gassen will continue to serve as president and chief executive officer of the combined organization. The partnership is expected to close sometime this year, subject to completion of regulatory processes and other customary closing conditions. (Link)
  5. The University of Pittsburgh Medical Center (UPMC), a Pittsburgh-headquartered nonprofit health care provider and insurer, and CommonSpirit Health, one of the nation’s largest nonprofit Catholic healthcare organizations, signed a definitive agreement transferring ownership of Steubenville, Ohio-based Trinity Health System to UPMC. UPMC and CommonSpirit Health have signed a definitive agreement transferring ownership of Trinity Health System to UPMC. The transfer includes Trinity West, Trinity East, Trinity St. Clairsville Neighborhood Hospital, Trinity Twin City Medical Center, and associated clinics, to UPMC. The transaction is expected to be completed in Fall 2026, pending regulatory review and customary closing conditions. The deal will allow UPMC to expand into the Midwest from its foothold in the mid-Atlantic. Financial terms were not disclosed. The deal marks UPMC’s first expansion into Ohio while supporting CommonSpirit’s multiyear asset-divestiture turnaround strategy. (Link)
  6. agilon health, inc. (NYSE: AGL), an Austin, TX-based value-based care platform partnering with primary care physicians on Medicare Advantage, saw its stock surge after delivering Q1 2026 revenue of $1.42 billion and GAAP EPS of $1.80, prompting upgrades from Deutsche Bank and Jefferies. agilon health (NYSE: AGL) shares surged sharply following a Q1 2026 earnings beat. Revenue came in at $1.42 billion versus analyst estimates of $1.38 billion, EPS (GAAP) of $1.80 crushed the consensus of $0.83, and Adjusted EBITDA of $53.84 million beat estimates of $36.15 million by nearly 49%. Deutsche Bank upgraded agilon health’s stock rating to Buy from Hold, raising its price target to $49.00, while Jefferies also upgraded the stock to Buy. For the full year, the company raised its 2026 Adjusted EBITDA guidance to $10–$40 million, with new CEO Tim O’Rourke commencing leadership. (Link)
  7. Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal Addus HomeCare Corporation (NASDAQ: ADUS), a Frisco, Texas-based provider of home and community-based personal care services, acquired HomeCourt Home Care, a Fort Wayne, Indiana-based non-medical home care agency. Addus HomeCare has entered the Indiana market through the acquisition of HomeCourt Home Care. The deal adds approximately $9.8 million in annualized revenue and expands Addus’ footprint into the Midwest with a strong regional provider of in-home personal care and supportive services for elderly and disabled clients. The transaction closed on May 1, 2026 and marks Addus’ continued geographic expansion strategy in the home-care sector. Financial terms were not disclosed. (Link)
  8. HealthVerity, Inc., a Philadelphia-based leader in privacy-protected real-world data exchange and patient identity solutions, entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data and analytics business formerly part of ICON plc (NASDAQ: ICLR). HealthVerity has announced the acquisition of Symphony Health to combine its clinical data depth with Symphony’s commercial insights, creating a unified, AI-ready platform for life sciences, payers, and government entities. The transaction, announced on May 5, 2026, is expected to close in May 2026 subject to customary closing conditions. Financial terms were not disclosed. (Link)
  9. Elsevier completes acquisition of Mytonomy and introduces comprehensive end to end patient engagement solutions for healthcare providers. Elsevier, a global leader in scientific publishing and health information solutions (part of RELX plc), completed the acquisition of Mytonomy, Inc., a Washington, D.C.-based provider of cloud-based video patient engagement and education platforms for hospitals and health systems. Elsevier has completed the acquisition of Mytonomy to integrate its clinical content libraries with Mytonomy’s video-first patient engagement platform, creating end-to-end solutions that improve adherence, reduce readmissions, and support value-based care across the care continuum. The deal, closed on May 5, 2026, combines Elsevier’s trusted evidence-based content with Mytonomy’s HIPAA-compliant, personalized video and interactive tools already deployed at more than 300 U.S. healthcare organizations. Financial terms were not disclosed. (Link)
  10. CQ Medical, the Avondale, Pennsylvania-based global leader in radiotherapy positioning solutions formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, acquired .decimal, a Sanford, Florida-based precision manufacturer of patient-specific radiotherapy beam-shaping devices. CQ Medical has acquired .decimal to expand its patient-specific cancer treatment portfolio. CQ Medical was formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, bringing together decades of expertise in essential radiation therapy positioning and immobilization solutions. Serving the radiotherapy clinical community for more than 40 years, .decimal is a trusted partner known for its rapid production of customized, patient-specific devices—typically manufactured and shipped within 1–2 days of order receipt. To date, the company has delivered over 500,000 patient-specific treatment devices, and actively serves more than 900 cancer centers across the United States. Financial terms were not disclosed. (Link)
  11. Med Tech Solutions (MTS), a Valencia, California-based managed healthcare IT services provider and portfolio company of Silversmith Capital Partners, acquired Avarion (formerly Huntzinger Management Group), a two-time Best in KLAS healthcare IT advisory firm, to span the full care continuum. Silversmith Capital Partners-backed Med Tech Solutions has acquired Avarion to strengthen its managed services platform. Med Tech Solutions, a provider of managed healthcare IT services and a portfolio company of Silversmith Capital Partners, acquired Avarion, a healthcare IT advisory firm serving hospitals, health systems and care networks. The combination unites MTS’ EHR managed services, application support, and technology infrastructure expertise with Avarion’s deep experience in healthcare IT advisory, consulting, and leadership services. Robert Kitts, Avarion’s CEO and founding partner, will report to Mona Abutaleb, CEO of MTS, and lead the company’s strategic advisory and staffing services. Financial terms were not disclosed. (Link)
  12. TimelyCare, a Fort Worth, TX-based virtual care provider for higher education serving nearly 500 campuses nationwide, acquired Alongside, a clinician-designed AI coaching platform trusted by more than 200 schools, to expand its student support model with continuous early-intervention AI coaching. TimelyCare has acquired Alongside, a clinician-designed AI coaching platform for students. Alongside combines evidence-based skill-building with proprietary safety models that detect risk and connect students to additional support when needed. Trusted by nearly 500 campuses across the U.S., TimelyCare combines URAC-accredited clinical standards with a measurement-based approach, while Alongside is trusted by more than 200 schools nationwide. The acquisition expands TimelyCare’s approach beyond traditional points of clinical need, positioning the company to engage a broader student population earlier and more consistently across the care continuum. Financial terms were not disclosed. (Link)
  13. Xpress Wellness, a Goldman Sachs-backed Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services, acquired Midwest Counseling Services, a Wichita, Kansas-based mental health clinic founded in 2022 serving older adults in senior communities. Goldman Sachs-backed Xpress Wellness has acquired Wichita-based Midwest Counseling Services. Founded in 2022, Midwest Counseling Services provides mental health services to older adults living in senior communities through approaches including talk therapy and individual counseling. Xpress Wellness is an Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services across rural and suburban communities. Lisa Harrison, founder of Midwest Counseling Services, now serves as Xpress Wellness’ Director of Operations of Post-Acute overseeing the Kansas market, with the deal expanding the acquirer’s behavioral health footprint in Kansas and adjacent states. (Link)
  14. Pediatrica Health Group, a Miami-based multi-site pediatric primary care platform backed by M33 Growth, acquired the long-established Westchester, Miami-Dade pediatric practice of Dr. Juan Ruiz-Unger to expand equitable access to care amid rising regional population growth. Pediatrica Health Group, backed by Boston-based venture and growth-stage investor M33 Growth, has acquired an additional pediatric practice in the Westchester neighborhood of Miami-Dade County. For over 40 years, Dr. Juan Ruiz-Unger has delivered compassionate, evidence-based care to Westchester families. Roberto Palenzuela, Chief Executive Officer of Pediatrica Health Group, said the acquisition aligns with the company’s goal of supporting physicians who want to expand access while maintaining continuity of care within their communities. Financial terms were not disclosed. The deal continues Pediatrica’s multi-site pediatric primary care roll-up strategy across South Florida. (Link)
  15. SpinLife, a Columbus, Ohio-based omni-channel mobility and home accessibility retailer owned by Brentwood, Tennessee-based Complex Rehab Technology leader Numotion, acquired Triton Medical and opened a new SpinLife retail store in Lady Lake, Florida, expanding its Central Florida footprint. Numotion-owned SpinLife has acquired Triton Medical and launched a new Central Florida retail location. SpinLife, owned by Numotion, said in a May 5 announcement that the acquisition was completed on April 22. The retail location is now operating as SpinLife — Lady Lake and strengthens the company’s presence in central Florida and enhancing service to the growing Lady Lake and The Villages communities. Matt Chesshire, Triton Medical’s founder, will remain at the Lady Lake store as general manager. Numotion acquired SpinLife in 2021. Financial terms were not disclosed. (Link)
  16. Care Advantage, Inc., a Mid-Atlantic-based privately held home care provider, announced the acquisition of First Priority Home Care, a Columbia, South Carolina-based non-medical home care agency, advancing its targeted expansion strategy across the Mid-Atlantic and Southeast. Care Advantage, Inc. has acquired Columbia, South Carolina-based First Priority Home Care. Care Advantage, one of the Mid-Atlantic’s largest privately held home care providers, today announced the acquisition of First Priority Home Care, based in Columbia, South Carolina. This latest transaction marks another step in Care Advantage’s continued expansion into the southern United States. First Priority Home Care is a non-medical home care agency based in Columbia, South Carolina, providing in-home support services to seniors and adults who need assistance. Financial terms of the deal were not disclosed. (Link)
  17. Standard Dental Labs Inc., (OTCQB:TUTH) an Orlando-based publicly traded dental laboratory consolidator, completed the acquisition of BRLIT Dental Laboratory, a Sarasota, Florida-based dental lab founded in 1977, adding approximately $886,000 in annual revenue. Standard Dental Labs Inc. (OTCQB: TUTH) has completed the acquisition of BRLIT Dental Laboratory in Sarasota, Florida. The transaction adds approximately $886,000 in annual revenue to Standard Dental Labs’ existing revenue base of approximately $236,000, bringing the company’s total annualized revenue to more than $1.1 million. The company holds a market capitalization of $6.54 million. BRLIT Dental Laboratory, founded in 1977, has served dentists throughout Florida for nearly five decades, and the acquisition expands the buyer’s footprint along Florida’s Gulf Coast. The company intends to continue pursuing strategic acquisitions in Florida’s dental laboratory industry. (Link)
  18. TopGum Industries Ltd. (TASE: TPGM), an Israel-based global leader in gummy-format dietary supplements, completed the acquisition of the U.S. gummy manufacturing operations of P&L Developments LLC, a Westbury, New York-based pharmaceutical and consumer healthcare CDMO, in a transaction valued at up to USD 35 million. TopGum Industries Ltd. (TASE: TPGM) has completed its acquisition of P&L Developments’ U.S. gummy manufacturing operations. The consideration, funded by TopGum’s existing resources, comprises US$10 million in cash at closing, 1,893,060 shares valued at approximately US$8 million at closing (based on a price of NIS 13 per share), and up to 4,022,751 additional shares (valued at up to US$17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones.  (Link)
  19. Arete Health Announces Acquisitions of Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults Arete Health, a physician-led multi-specialty practice management platform, acquired Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults, two established physical therapy practices in Virginia. Arete Health has completed the acquisition of two Virginia-based physical therapy practices—Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults—on May 5, 2026. The deals strengthen Arete’s outpatient rehabilitation footprint in the Mid-Atlantic and add specialized orthopedic, sports medicine, and balance therapy services. The combined practices serve several hundred patients weekly across multiple locations. Financial terms were not disclosed. (Link)

Venture Deals and Other

  1. Basata, a Phoenix-based AI company building the operational layer for U.S. healthcare, raised a $21 million Series A led by Basis Set Ventures with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger, bringing total funding to $24.5 million. Basata has closed a $21 million Series A funding round to scale its AI-driven healthcare administrative automation platform. The Series A was led by Basis Set Ventures, with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger. The round brings total funding to $24.5 million. Basis Set Ventures’ Lan Xuezhao led the round, joined by Cowboy Ventures’ Aileen Lee, PHX Ventures, Zenda Capital, and Victoria Treyger. The company has served more than 500,000 patients to date, including 100,000 patients during the past month alone, while working with specialty groups across cardiology, urology, gastroenterology, and ophthalmology. (Link)
  2. Dandelion Health, a New York-based clinical intelligence platform serving life sciences, raised a $14 million Series A led by Healthier Capital with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures, to scale its multimodal clinical AI infrastructure. Dandelion Health has secured $14 million in Series A funding. Healthier Capital led the round, with participation from Colle Capital and existing investors Moxxie Ventures, Convergent Ventures and Primary Venture Partners. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. The Series A financing will be used to expand Dandelion’s pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. (Link)
  3. Enzo Health, a Lehi, Utah-based AI-driven platform for home health and post-acute care launched in 2024, raised a $20 million Series A led by global venture capital firm N47 with participation from existing investors Gradient (a Google-affiliated investment firm), Tandem Ventures, and Rigby Watts, bringing total funding to $26 million. Enzo Health has raised a $20 million Series A funding round. The round was led by N47, bringing the company’s total funding to $26M. Existing investors Gradient, Tandem Ventures, and Rigby Watts also participated. Existing investors Gradient (Palo Alto, a Google-affiliated investment firm), Tandem Ventures (Draper, UT), and Rigby Watts (Millcreek, UT) also participated. Launched in 2024, Enzo Health has grown revenue by more than 40X in twelve months and is now used by organizations that support over 500,000 patients annually. The funds will accelerate expansion into skilled nursing and hospice sectors. (Link)
  4. Travv, a Stillwater, Oklahoma-based AI-native diagnostic platform for veterinary medicine led by founder and CEO Derick Whitley, DVM, DACVP, closed a $1.6 million seed funding round led by Digitalis Ventures with participation from AniVC, to advance its cloud-based veterinary diagnostic platform. Travv has closed a $1.6 million seed funding round. Travv, a Stillwater, OK-based provider of an AI-native diagnostic platform for veterinary medicine, closed a $1.6m seed funding round. The round was led by Digitalis Ventures, with participation from AniVC. The funding will support continued development of Travv’s AI-native diagnostic platform for veterinary medicine, including product expansion, hospital onboarding, commercial growth, and key integrations. Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across life sciences, health technology & services, and animal health, while AniVC focuses on early-stage pet companies. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)